Pfizer vs Tata Motors: Revenue, Profit and Business Model
Pfizer reported $62.6B of revenue in FY2025 and $7.8B of net income. Tata Motors reported ~$9.7B of revenue in FY2026 and ~$351.5M of net income.
Latest financial snapshot
Pfizer
- Latest revenue
- $62.6B (FY2025)
- Net income
- $7.8B
- Net margin
- 12.4%
- Revenue growth
- +1.9% a year, FY2016–FY2025
Tata Motors
- Latest revenue
- ~$9.7B (FY2026)
- Net income
- ~$351.5M
- Net margin
- 3.6%
- Revenue growth
- +3.2% a year, FY2024–FY2026
Financial summary
Pfizer
Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%.
Tata Motors
The post-demerger Tata Motors Limited reported FY2026 (year to March 31, 2026) revenue from operations of ~$9.73B (INR83,855 Cr), up 44% from ~$6.75B (INR58,217 Cr), as wholesales rose 14% to about 428,000 units. The jump partly reflects the changed perimeter after the demerger, so it is not a clean like-for-like growth rate. Profit for the year fell 5.2% to ~$351M (INR3,030 Cr), weighed by one-time demerger costs (about $111M (INR960 Cr) in Q3) and new labour-code charges. Momentum carried into Q1 FY2027: revenue rose about 20% to ~$2.39B (INR20,576 Cr) and attributable profit rose 83% to ~$297M (INR2,560 Cr), helped by a one-time gain linked to Tata Capital, while commodity costs squeezed margins.
Revenue and profit by year
Pfizer
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | 12.4% | -1.6% | Source |
| FY2024 | $63.6B | $8B | 12.6% | +6.8% | Source |
| FY2023 | $59.6B | $2.1B | 3.6% | -41.1% | Source |
| FY2022 | $101.2B | $31.4B | 31.0% | +24.5% | Source |
| FY2021 | $81.3B | $22B | 27.0% | +95.2% | Source |
| FY2020 | $41.7B | $9.2B | 22.0% | +1.8% | Source |
| FY2019 | $40.9B | $16B | 39.2% | +0.2% | Source |
| FY2018 | $40.8B | $11.2B | 27.3% | -22.3% | Source |
| FY2017 | $52.5B | $21.3B | 40.6% | -0.5% | Source |
| FY2016 | $52.8B | $7.2B | 13.7% | — | Source |
Tata Motors
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2026 | ~$9.7B | ~$351.5M | 3.6% | +44.0% | Source |
| FY2025 | ~$6.8B | ~$370.6M | 5.5% | -26.1% | Source |
| FY2024 | ~$9.1B | — | 0.0% | — | Source |
Where the revenue comes from
Pfizer
- Patented medicines
Core revenue
Prescription drugs protected by exclusivity and clinical differentiation.
- Vaccines
Major revenue contributor
Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.
- Oncology
Strategic growth driver
Cancer medicines, antibody-drug conjugates, and Seagen-related assets.
- Hospital and anti-infective products
Meaningful contributor
Sterile injectables, anti-infectives, and hospital therapies.
- Collaborations and alliances
Supplemental
Co-promoted products and partnered scientific platforms.
Tata Motors
- Trucks and small commercial vehicles
Primary revenue source
Revenue from trucks, pickups, small commercial vehicles and heavy vehicles.
- Buses and vans
Major segment
Bus and van sales to public transport, schools, fleets and private operators.
- Spares and services
Recurring support stream
Parts, maintenance, service contracts, uptime products and dealer service revenue.
- Connected and non-vehicular businesses
Strategic growth stream
Fleet Edge, Tata OK, aggregates and other mobility services.
Business model and strategy
Pfizer
How it makes money
Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates.
Growth strategy
Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).
Competitive advantage
Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses.
Tata Motors
How it makes money
Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition.
Growth strategy
Tata Motors is growing through next-generation trucks, buses, electric and alternative-fuel commercial vehicles, Fleet Edge, service parts, exports, operational discipline and the planned Iveco expansion.
Competitive advantage
Tata Motors' advantage is its scale in Indian commercial vehicles, deep dealer and service reach, Tata brand trust, engineering base and ability to bundle vehicles, spares, fleet tools and service.
Questions about Pfizer vs Tata Motors
Which company has higher revenue — Pfizer Inc. or Tata Motors Limited?
Pfizer Inc. reported $62.6B (FY2025), while Tata Motors Limited reported ~$9.7B (FY2026). By last reported revenue, Pfizer Inc. is the larger business, with Tata Motors Limited reporting a smaller revenue base. Note: these are from different fiscal years and are not a direct like-for-like comparison.
What is the market cap of Pfizer Inc. vs Tata Motors Limited?
Pfizer Inc.'s market capitalisation stands at $160.3B, while Tata Motors Limited's is $17.5B. Pfizer Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Tata Motors Limited.
Which is more financially efficient — Pfizer Inc. or Tata Motors Limited?
Pfizer Inc. generates $834k / employee in revenue per employee, while Tata Motors Limited generates $240k / employee. Pfizer Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Pfizer Inc. and Tata Motors Limited make money?
Pfizer Inc. and Tata Motors Limited generate revenue in fundamentally different ways. Pfizer Inc.: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Tata Motors Limited: Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition.
Which company is valued higher relative to revenue — Pfizer Inc. or Tata Motors Limited?
On a price-to-sales (P/S) basis, Pfizer Inc. trades at 2.6x P/S and Tata Motors Limited at 1.8x P/S. Pfizer Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Tata Motors Limited. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Pfizer Inc. bigger than Tata Motors Limited?
By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to Tata Motors Limited (~$9.7B (FY2026)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Pfizer vs Tata Motors overview